Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

About this update from Vor Biopharma Inc.

[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B2LYyFLcnDdgjzJKo4HDhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":135,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"$55.6 million private placement completed in December 2024","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":163,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.","length":260,"tagName":"p"},{"type":"text","content":"“We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our clinical trials reinforces our confidence in the potential of trem-cel and VCAR33 to transform the treatment landscape,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “With a strengthened financial position from recent investment by new investor Reid Hoffman and existing investor RA Capital Management, we are well-positioned to drive our mission forward and deliver meaningful impact to patients.”","length":555,"tagName":"p"},{"type":"text","content":"Corporate Updates","length":17,"tagName":"p"},{"type":"text","content":"Trem-cel + Mylotarg (VBP101) Clinical Trial ","length":43,"tagName":"p"},{"type":"text","content":"Trem-cel is a shielded transplant in development for patients with AML and MDS, i...

More updates from Vor Biopharma Inc.